Photo from wikipedia
5 years after its first approval by a stringent regulatory authority, the role of bedaquiline in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is well established,… Click to show full abstract
5 years after its first approval by a stringent regulatory authority, the role of bedaquiline in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is well established, and acknowledged by existing guidance. However, in many regards, the global introduction of bedaquiline can hardly be considered as a success. Scale-up of introduction of bedaquiline, as part of optimised treatment regimens, is supported by growing evidence http://ow.ly/JCEV30aPLmq
Journal Title: European Respiratory Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!